Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
NCT04932434Phase 2Completed
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), anxiety disorder. Started Aug 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT04932434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932434.